secwatch.observer — SEC 8-K summary
======================================

Issuer:     PTC THERAPEUTICS, INC. (PTCT)
CIK:        0001070081
Form:       8-K
Filed at:   2023-10-26T23:59:59+00:00
Accession:  0001070081-23-000063
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PTC Therapeutics Q3 total revenues $196.6M (-9% YoY), net loss $133M; updates pipeline timelines
--------------------------------------------------------------------------------

- DMD franchise revenue $136M in Q3; full-year 2023 DMD guidance raised to $565-595M.
- Translarna net revenue $69M; CHMP re-examination expected Jan 2024; FDA type C meeting in Q4 2023.
- Sepiapterin NDA submission for PKU delayed to no later than Q3 2024; MAA to EMA in H1 2024.
- PTC518 HD trial enrollment ongoing; FDA requires 6-month safety data for US dosing.
- Total 2023 revenue guidance $940M-$1.0B; GAAP R&D+SG&A expenses $915-965M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1070081/000107008123000063/0001070081-23-000063-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1070081/000107008123000063/tmb-20231026x8k.htm
  HTML page:      https://secwatch.observer/filing/0001070081-23-000063

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer